Positive Early Signs For Acumen’s Bid To Go Beyond Leqembi In Alzheimer’s

Drugs Targets Most Toxic Amyloid Form

Phase I data shows the oligomer-targeting antibody was safe and effective, and Acumen will now move ahead to a potentially pivotal Phase II/III study in Alzheimer’s disease.

Now that Eisai and Biogen’s Leqembi (lecanemab) has gained full US approval and Lilly’s donanemab is not far behind, other companies are looking to develop safer and more effective rivals in the same amyloid-beta targeting class.

One of the most fancied pre-market companies is Acumen Pharmaceuticals, led by a group of ex-Lilly executives. Its antibody candidate, ACU193, targets amyloid-beta oligomers, believed to be the most toxic form of the protein, an approach it hopes can take safety and efficacy to the next level

Leo Roars To A Profit In Q1 As Adbry Grows In US

15 May 2025

• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

13 May 2025

• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

12 May 2025

• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

12 May 2025

• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.